01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Working with argan cake: a new etiology for hypersensitivity pneumonitis
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Electronic supplementary material
Competing interests
Authors’ contributions
Background
Methods
Description of the industrial process
Data collection
Culture and antigen extracts
Serology techniques
Results
Cases
|
Gender (age)
|
Tobacco status
|
Domestic argan exposure
|
Workstation
|
First exposure to argan
|
Frequency of exposure to argan granule
|
Last exposure to argan
|
Complaints suggestive of HP
|
Onset and duration of complaints suggestive of HP
|
---|---|---|---|---|---|---|---|---|---|
1
|
Male (35)
|
S
|
No
|
production operator
|
2006
|
monthly
|
previous month
|
flu-like syndrome
|
Early evening and for several hours
|
2
|
Male (28)
|
FS
|
No
|
production operator
|
2008
|
monthly
|
previous month
|
flu-like syndrome
|
Early evening and for several hours
|
3
|
Male (35)
|
FS
|
No
|
production operator
|
2007
|
monthly
|
previous month
|
flu-like syndrome
|
Early evening and for several hours
|
4
|
Male (39)
|
FS
|
No
|
production (foreman)
|
2007
|
monthly
|
previous month
|
flu-like syndrome
|
Early evening and for several hours
|
5
|
Male (30)
|
S
|
No
|
production operator
|
2007
|
occasionally
|
previous month
|
No
|
/
|
6
|
Male (35)
|
S
|
No
|
production operator
|
2007
|
monthly
|
previous month
|
No
|
/
|
7
|
Male (45)
|
S
|
No
|
“powder” workshop
|
2006
|
occasionally
|
previous month
|
No
|
/
|
8
|
Female (40)
|
NS
|
No
|
packaging
|
2007
|
monthly
|
previous month
|
No
|
/
|
9
|
Male (34)
|
NS
|
No
|
production operator
|
2006
|
occasionally
|
previous month
|
flu-like syndrome
|
Early evening and for several hours
|
Before specific challenge
|
After specific challenge *
|
|||||||
---|---|---|---|---|---|---|---|---|
Cases
|
Physical examination
|
Chest X rays
|
DLCO
|
Symptoms suggestive of HP
†
|
DLCO (variation) % predicted
†
|
CT Scan
†
|
BAL
‡
|
Conclusion
|
1
|
normal
|
normal
|
89%
|
Yes
|
78% (-11%)
|
No specific abnormalities
|
600000/mL 25.5% lymphocytes
|
HP
|
2
|
normal
|
normal
|
118%
|
Yes
|
120%
|
/
|
/
|
ODTS
|
3
|
normal
|
normal
|
63%
|
Yes
|
61%
|
Emphysema
|
935000/mL 5% lymphocytes
|
ODTS
|
4
|
normal
|
normal
|
88%
|
Yes
|
62% (-22%)
|
Localized Ground-glass opacities
|
600000/mL 18% lymphocytes (not available)
|
HP
|
5
|
normal
|
normal
|
68%
|
Yes
|
79%
|
/
|
/
|
ODTS
|
6
|
normal
|
normal
|
85%
|
/
|
/
|
/
|
/
|
/
|
7
|
normal
|
normal
|
79%
|
/
|
/
|
/
|
/
|
/
|
8
|
normal
|
normal
|
86%
|
/
|
/
|
/
|
/
|
/
|
9
|
normal
|
normal
|
95%
|
Yes
|
94%
|
/
|
/
|
ODTS
|
Microbiological results
Serology results
Case
|
Precipitin arcs n
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Argan granulates
|
Argan powder
|
Sterile finished product
|
Bacillusspp
|
Streptomyces marokkonensis
|
||||||
ES*
|
DD
†
|
ES
|
DD
|
ES
|
DD
|
ES
|
DD
|
ES
|
DD
|
|
Workers exposed to Argan
|
||||||||||
1
|
7
|
4
|
3
|
4
|
1
|
1
|
0
|
1
|
0
|
0
|
2
|
2
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
1
|
0
|
3
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
2
|
0
|
0
|
4
|
5
|
2
|
3
|
2
|
0
|
0
|
0
|
1
|
1
|
0
|
5
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
0
|
6
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
7
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
8
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
9
|
4
|
3
|
3
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
Non exposed Controls
|
||||||||||
1 (serum pool
‡)
|
1
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
Case
|
Total IgE (IU/ml)
|
Average IgG
|
||||
---|---|---|---|---|---|---|
Argan granule Ag (ARG Ag)
|
Argan powder Ag (ARP Ag)
|
Argantensyl Ag (ART Ag)
|
Bacillusspp. Ag
|
Streptomyces. marokkonensisAg
|
||
Workers exposed to Argan
|
||||||
1
|
80
|
2.48
|
2.37
|
3.25
|
0.13
|
0.10
|
2
|
559
|
1.10
|
1.00
|
0.55
|
0.12
|
0.13
|
3
|
261
|
1.17
|
0.94
|
0.22
|
0.10
|
0.29
|
4
|
144
|
0.96
|
1.48
|
1.48
|
0.10
|
0.14
|
5
|
100
|
1.30
|
1.03
|
0.27
|
0.10
|
0.19
|
6
|
47
|
1.52
|
0.92
|
0.45
|
0.11
|
0.09
|
7
|
21
|
0.14
|
0.22
|
0.14
|
0.13
|
0.09
|
8
|
65
|
0.51
|
0.56
|
0.28
|
0.10
|
0.10
|
9
|
112
|
1.49
|
1.25
|
1.12
|
0.13
|
0.09
|
Non exposed controls
|
||||||
1 (serum pool*)
|
/
|
0.45
|
0.62
|
0.22
|
0.14
|
0.11
|